BCTX (BriaCell Therapeutics) EBIT per Share : $-2.03 (TTM As of Jul. 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics EBIT per Share?

BriaCell Therapeutics's EBIT per Share for the three months ended in Jul. 2024 was $-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Jul. 2024 was $-2.03.

During the past 3 years, the average EBIT per Share Growth Rate was -12.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 27.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was 18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BriaCell Therapeutics's EBIT per Share or its related term are showing as below:

BCTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -80.1 Med: 7.2 Max: 51.9
Current: -12.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BriaCell Therapeutics was 51.90% per year. The lowest was -80.10% per year. And the median was 7.20% per year.

BCTX's 3-Year EBIT Growth Rate is ranked worse than
69.31% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs BCTX: -12.80

BriaCell Therapeutics's EBIT for the three months ended in Jul. 2024 was $-5.77 Mil.

BriaCell Therapeutics EBIT per Share Historical Data

The historical data trend for BriaCell Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics EBIT per Share Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

EBIT per Share

Get a 7-Day Free Trial

-5.60

-3.04

-1.73

-1.49

-2.03

BriaCell Therapeutics Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
EBIT per Share	Get a 7-Day Free Trial															-0.48	-0.51	-0.62	-0.58	-0.32

BriaCell Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BriaCell Therapeutics's EBIT per Share for the fiscal year that ended in Jul. 2024 is calculated as

	EBIT per Share		(A: Jul. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-33.33	/	16.455
=	-2.03

BriaCell Therapeutics's EBIT per Share for the quarter that ended in Jul. 2024 is calculated as

	EBIT per Share		(Q: Jul. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.768	/	17.875
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.03

BriaCell Therapeutics (NAS:BCTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BriaCell Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

8BT:Germany BCT:Canada

Address

235 - 15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0